Author:
Perini Guilherme Fleury,Korin Laura,Schmidt Joaquin Diaz
Reference9 articles.
1. Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies;Ermann;Blood,2023
2. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle. cell lymphoma: an international, randomised, open-label, phase 3 study;Dreyling;Lancet,2016
3. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma;Wang;N Engl J Med,2022
4. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
5. Clinical Outcomes of Patients With B-cell Non-Hodgkin Lymphoma in Real-world Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study;Pavlovsky;JCO Glob Oncol,2022